The dawn of 2026 marks a historic turning point in drug safety testing as major US pharmaceutical companies begin substituting traditional animal models with 3D bioprinted human liver tissue. These "livers-on-a-chip" provide a more accurate representation of human metabolic pathways, allowing for earlier detection of hepatotoxicity, which is a leading cause of drug failure during clinical...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)